{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:15:53Z","timestamp":1793164553004,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00296-021-04847-x","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T07:02:52Z","timestamp":1617433372000},"page":"1115-1124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-8828","authenticated-orcid":false,"given":"Stefanie D.","family":"Wade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-3826","authenticated-orcid":false,"given":"Vasileios C.","family":"Kyttaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,3]]},"reference":[{"issue":"2","key":"4847_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","volume":"122","author":"JH Anolik","year":"2007","unstructured":"Anolik JH, Friedberg JW, Zheng B et al (2007) B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 122(2):139\u2013145","journal-title":"Clin Immunol"},{"issue":"25","key":"4847_CR2","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572\u20132581","journal-title":"N Engl J Med"},{"issue":"9","key":"4847_CR3","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793\u20132806","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4847_CR4","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54(5):1390\u20131400","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4847_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221\u2013232","journal-title":"N Engl J Med"},{"issue":"6","key":"4847_CR6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736\u2013745","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4847_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","volume":"11","author":"C Diaz-Lagares","year":"2012","unstructured":"Diaz-Lagares C, Croca S, Sangle S et al (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11(5):357\u2013364","journal-title":"Autoimmun Rev"},{"issue":"7","key":"4847_CR8","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1093\/ndt\/gfp002","volume":"24","author":"JN Boletis","year":"2009","unstructured":"Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP (2009) Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 24(7):2157\u20132160","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"4847_CR9","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1002\/art.27541","volume":"62","author":"B Terrier","year":"2010","unstructured":"Terrier B, Amoura Z, Ravaud P et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 62(8):2458\u20132466","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4847_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369(5):417\u2013427","journal-title":"N Engl J Med"},{"issue":"19","key":"4847_CR11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771\u20131780","journal-title":"N Engl J Med"},{"issue":"1","key":"4847_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4847_CR13","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215\u20131226","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4847_CR14","doi-asserted-by":"publisher","first-page":"e025687","DOI":"10.1136\/bmjopen-2018-025687","volume":"9","author":"YKO Teng","year":"2019","unstructured":"Teng YKO, Bruce IN, Diamond B et al (2019) Phase III, multicentre, randomized, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open 9(3):e025687","journal-title":"BMJ Open"},{"issue":"6","key":"4847_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","volume":"36","author":"EAA Christou","year":"2017","unstructured":"Christou EAA, Giardino G, Worth A, Ladomenou F (2017) Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. Int Rev Immunol 36(6):352\u2013359","journal-title":"Int Rev Immunol"},{"issue":"6","key":"4847_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(6):909\u2013920","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4847_CR17","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/rheumatology\/key394","volume":"58","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Jayne DR, Mukhtyar C et al (2019) Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology 58(5):889\u2013896","journal-title":"Rheumatology"},{"issue":"4","key":"4847_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.semarthrit.2006.09.005","volume":"36","author":"M Fernandez-Castro","year":"2007","unstructured":"Fernandez-Castro M, Mellor-Pita S, Citores MJ et al (2007) Common variable immunodeficiency in systemic lupus erythematosus. Semin Arthritis Rheum 36(4):238\u2013245","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"4847_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","volume":"19","author":"J Thiel","year":"2017","unstructured":"Thiel J, Rizzi M, Engesser M et al (2017) B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther 19(1):101","journal-title":"Arthritis Res Ther"},{"key":"4847_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2474-15-178","volume":"15","author":"H Marco","year":"2014","unstructured":"Marco H, Smith RM, Jones RB et al (2014) The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 15:178","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"4847_CR21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/art.40032","volume":"69","author":"FB Cortazar","year":"2017","unstructured":"Cortazar FB, Pendergraft WF 3rd, Wenger J, Owens CT, Laliberte K, Niles JL (2017) Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 69(5):1045\u20131053","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"4847_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","volume":"51","author":"I De La Torre","year":"2012","unstructured":"De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G (2012) Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology 51(5):833\u2013840","journal-title":"Rheumatology"},{"issue":"6","key":"4847_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/acr.22993","volume":"69","author":"V Reddy","year":"2017","unstructured":"Reddy V, Martinez L, Isenberg DA, Leandro MJ, Cambridge G (2017) Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long-term effects on serum immunoglobulins. Arthritis Care Res (Hoboken) 69(6):857\u2013866","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"suppl","key":"4847_CR24","first-page":"10","volume":"72","author":"A Garc\u00eda-Fern\u00e1ndez","year":"2020","unstructured":"Garc\u00eda-Fern\u00e1ndez A, L\u00f3pez-Guti\u00e9rrez F, Loarce-Martos J et al (2020) Cohort of rheumatic patients treated with rituximab and COVID-19: Does rituximab treatment increases the severity of SARS-COV2 Infection? [abstract]. Arthritis Rheumatol 72(suppl):10","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"4847_CR25","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.40937","volume":"71","author":"MY Md Yusof","year":"2019","unstructured":"Md Yusof MY, Vital EM, McElvenny DM et al (2019) Predicting Severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 71(11):1812\u20131823","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"4847_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","volume":"380","author":"K Iversen","year":"2019","unstructured":"Iversen K, Ihlemann N, Gill SU et al (2019) Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med 380(5):415\u2013424","journal-title":"N Engl J Med"},{"issue":"5","key":"4847_CR27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"HK Li","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R et al (2019) Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med 380(5):425\u2013436","journal-title":"N Engl J Med"},{"issue":"7","key":"4847_CR28","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10067-019-04557-7","volume":"38","author":"AC Duarte","year":"2019","unstructured":"Duarte AC, Cordeiro A, Fernandes BM et al (2019) Rituximab in connective tissue disease-associated interstitial lung disease. Clin Rheumatol 38(7):2001\u20132009","journal-title":"Clin Rheumatol"},{"issue":"2","key":"4847_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","volume":"48","author":"G Boleto","year":"2018","unstructured":"Boleto G, Avouac J, Wipff J et al (2018) Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study. Semin Arthritis Rheum 48(2):149\u2013154","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"4847_CR30","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","volume":"62","author":"JE Gottenberg","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T et al (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62(9):2625\u20132632","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4847_CR31","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169","journal-title":"JAMA Netw Open"},{"issue":"10","key":"4847_CR32","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","volume":"53","author":"E Besada","year":"2014","unstructured":"Besada E, Koldingsnes W, Nossent JC (2014) Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology 53(10):1818\u20131824","journal-title":"Rheumatology"},{"issue":"3","key":"4847_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/rheumatology\/kex446","volume":"57","author":"J Henry","year":"2018","unstructured":"Henry J, Gottenberg JE, Rouanet S et al (2018) Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. Rheumatology 57(3):538\u2013547","journal-title":"Rheumatology"},{"key":"4847_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM et al (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60\u201365","journal-title":"J Autoimmun"},{"issue":"3","key":"4847_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jbspin.2016.03.013","volume":"84","author":"M Assala","year":"2017","unstructured":"Assala M, Groh M, Blanche P et al (2017) Pneumococcal and influenza vaccination rates in patients treated with corticosteroids and\/or immunosuppressive therapies for systemic autoimmune diseases: a cross-sectional study. Jt Bone Spine 84(3):365\u2013366","journal-title":"Jt Bone Spine"},{"issue":"1","key":"4847_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39\u201352","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4847_CR37","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jaci.2015.06.035","volume":"136","author":"S Barmettler","year":"2015","unstructured":"Barmettler S, Price C (2015) Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab\u2013for how long? J Allergy Clin Immunol 136(5):1407\u20131409","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"4847_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3899\/jrheum.180784","volume":"46","author":"KA Papp","year":"2019","unstructured":"Papp KA, Haraoui B, Kumar D et al (2019) Vaccination guidelines for patients with immune-mediated disorders taking immunosuppressive therapies: executive summary. J Rheumatol 46(7):751\u2013754","journal-title":"J Rheumatol"},{"issue":"4","key":"4847_CR39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nri2729","volume":"10","author":"FE Lund","year":"2010","unstructured":"Lund FE, Randall TD (2010) Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 10(4):236\u2013247","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4847_CR40","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15(10):1143\u20131238","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"4847_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.autrev.2019.03.010","volume":"18","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Mukhtyar C, Jayne D et al (2019) Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review. Autoimmun Rev 18(5):535\u2013541","journal-title":"Autoimmun Rev"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04847-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04847-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04847-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:03:12Z","timestamp":1744185792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04847-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,3]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4847"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04847-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,3]]},"assertion":[{"value":"15 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SDW: None. VCK: No direct conflicts of interest. Dr. Kyttaris has received consulting fees from GlaxoSmithKline and Exagen Diagnostics for work unrelated to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"IRB approval was obtained from Beth Israel Deaconess Medical Center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The manuscript has been read and approved for publication by all named authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}